Compare Amgen, Inc. (AMGN) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Gartner Inc — how do they compare? Amgen, Inc. trades at $356.16 (market cap $196.12B), while Gartner Inc trades at $139.75 (market cap $8.92B). The key difference: Amgen, Inc. is far larger — about 22× Gartner Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Gartner Inc pays none. Which is the better fit depends on your goals.
| AMGN | IT | |
|---|---|---|
Market Cap | $196.12B | $8.92B |
Sector | Health | Technology |
52-Week High | $388.16 | $374.40 |
52-Week Low | $271.18 | $125.68 |
Enterprise Value | $241.41B | $10.51B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Gartner (IT) trades at $133.24, up 0.41% today, with a bearish technical signal but strong recent earnings beats. The company shows robust profitability with a 68.99% gross margin and 11.44% net margin, though 2025 net income declined to $729M from $1.3B in 2024. Analyst consensus is mixed with a $157.60 price target, while news highlights ongoing investigations and industry events.
Outlook is cautious due to technical bearishness and net cash outflows, but valuation appears reasonable with a P/E of 13.17. Risks include competitive pressures and the recent legal investigation. Upside potential exists if earnings momentum continues and sentiment improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
